CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading ->